


► SECOND ANNOUNCEMENT ◀

34th Symposium on
**Medicinal Chemistry
in Eastern England**



Thursday 27th April, 2023

Fielder Centre, Hatfield, UK



Synopsis

Known colloquially as the “Hatfield MedChem” meeting, this is a highly successful, long-standing, one-day meeting that runs annually. The scientific program will comprise presentations showcasing medicinal chemistry case studies from tools to candidates, across a range of modalities, therapeutic areas and target classes, as well as covering more general topics at the forefront of drug discovery. The meeting aims to be informal and interactive, and is ideal for all those working in medicinal chemistry and drug discovery more widely.

Programme

09:00 REGISTRATION / COFFEE

MORNING SESSION

Chair: **Simon Ward**, Medicines Discovery Institute, Cardiff University, UK

09:30 Welcome and Introduction

09:40 *Identification of H4R Antagonist HTL0032547 as a potential therapy for Atopic Dermatitis*
Charlotte Fieldhouse, Heptares, UK

10:20 *Optimisation of aminofurazans leading to orally bioavailable and CNS penetrant inhibitors of MSK-1 (Mitogen and Stress-Activated Kinase 1)*
Anne Valade, UCB, Belgium

REFRESHMENTS

11:30 *Isoform-Selective EPAC Activators: Therapeutic Opportunities for Cardiopulmonary Inflammation*
Graeme Barker, Heriot-Watt University, UK

11:55 *Discovery of novel LpxA inhibitors targeting Pseudomonas aeruginosa*
Alastair Parkes, Evotec, UK

12:20 *Electrostatic Complementarity in Structure-Based Drug Design*
James Day, Astex, UK

12:45 LUNCH

AFTERNOON SESSION

Chair: **Margarita Puente-Felipe**, GSK, Spain

14:15 *Next Generation Antibody-Drug Conjugates*
David Spring, Cambridge University, UK

14:55 *AI-driven approach to the discovery of novel Mpro inhibitors with high pan-coronavirus activity*
Marco Derudas, ExScientia, UK

REFRESHMENTS

15:50 *Combining surface chemistry with affinity selection mass spectrometry accelerates drug discovery for protein and oligonucleotide targets*
Zachary Gurard-Levin, SAMDI Tech a Charles River company, US

16:15 *Discovery and Optimisation of Potent and Selective Inhibitors Targeting EGFR Exon20 Insertion Mutations*
Clare Thomson, AstraZeneca, UK

16:55 Concluding Remarks

17:00 Meeting Close

Organising Committee



Adrian Hall
UCB
(Treasurer)



Nicole Hamblin
Charles River
(Chair)



David Hirst
MSD

Secretariat contact:

Hg3 Conferences
events@hg3.co.uk • +44 (0) 1423 529333

To find out more, visit the BMCS website by using the URL or by scanning the QR code here:

www.rscbmcs.org/events/mcee-2/



SCAN ME

Sponsors

Sponsors are encouraged to support this popular event.

AstraZeneca

charles river

charnwood molecular
for the discovery



EUROPEAN FEDERATION
FOR MEDICINAL CHEMISTRY
AND CHEMICAL BIOLOGY



pharמידex
world-leading translational research